AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34225296 — intervention group
Group type: EXPERIMENTAL
Intervention: Firearm weapon carriage at 3- and 6-months postinjury
Number of subjects: 128
Study 32370778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone continuation
Number of subjects: 223
Study 32370778 — intervention group
Group type: COMPARATOR
Intervention: Risperidone switch to Lurasidone
Number of subjects: 223
Study 32370778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone continuation (males)
Number of subjects: 223
Study 32370778 — intervention group
Group type: COMPARATOR
Intervention: Risperidone switch to Lurasidone (males)
Number of subjects: 223
Study 32370778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone continuation (females)
Number of subjects: 223
Study 32370778 — intervention group
Group type: COMPARATOR
Intervention: Risperidone switch to Lurasidone (females)
Number of subjects: 223
Study 35728875 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally two times daily and trametinib 2 mg orally one time daily
Number of subjects: 532
Study 35728875 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dabrafenib and trametinib
Number of subjects: 532
Study 33759278 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (digital image altered to match patient's desired hand appearance)
Number of subjects: 45
Study 33759278 — intervention group
Group type: COMPARATOR
Intervention: Control group (unaltered image)
Number of subjects: 45
Study 33759278 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (follow-up after repeated interventions)
Number of subjects: 45
Study 33759278 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow-up after repeated interventions)
Number of subjects: 45
Study 32675595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 32675595 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0
Study 32675595 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 0
Study 32224742 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic leakage in rectal cancer patients
Number of subjects: 0
Study 32224742 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic leakage in colon cancer patients
Number of subjects: 0
Study 34441967 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 30
Study 34441967 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid (triamcinolone 0.05%)
Number of subjects: 30
Study 32678062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing of FIT kits
Number of subjects: 165
Study 32678062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing of FIT kits plus CHR outreach
Number of subjects: 165
Study 32678062 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 165
Study 36250667 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher use in low copay group
Number of subjects: 7351
Study 36250667 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher use in middle copay group
Number of subjects: 7351
Study 36250667 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher use in high copay group
Number of subjects: 7351
Study 36250667 — intervention group
Group type: COMPARATOR
Intervention: High copay group without voucher
Number of subjects: 7351
Study 33331846 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane chemotherapy with indoximod
Number of subjects: 0
Study 33331846 — intervention group
Group type: COMPARATOR
Intervention: Taxane chemotherapy without indoximod (control)
Number of subjects: 0
Study 35138648 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month dental home visits and education leaflets
Number of subjects: 176
Study 35138648 — intervention group
Group type: COMPARATOR
Intervention: education leaflets alone
Number of subjects: 176
Study 34554106 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP/NX-F with Incentivized Abstinence and Adherence Monitoring (experimental, n=70)
Number of subjects: 141
Study 34554106 — intervention group
Group type: COMPARATOR
Intervention: BUP/NX-F in usual care (control, n=71)
Number of subjects: 141
Study 36418750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity walking on a treadmill up to volitional exhaustion
Number of subjects: 10
Study 36418750 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking with individually selected speed for 20 min
Number of subjects: 10
Study 34181478 — intervention group
Group type: EXPERIMENTAL
Intervention: 372 mg ISAVUSULF intravenous solution via nasogastric tube
Number of subjects: 0
Study 34181478 — intervention group
Group type: COMPARATOR
Intervention: 372 mg ISAVUSULF capsules for oral administration
Number of subjects: 0
Study 32679239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Spo2
Number of subjects: 2687
Study 32679239 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Spo2
Number of subjects: 2687
Study 32679239 — intervention group
Group type: EXPERIMENTAL
Intervention: Desaturation duration and desaturation/resaturation time ratio
Number of subjects: 2687
Study 35940738 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0
Study 35940738 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 0
Study 35940738 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 32919046 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal rotation at 30° in scapular plane elevation
Number of subjects: 9
Study 32919046 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal adduction at 60° of elevation
Number of subjects: 9
Study 32919046 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal rotation at 30° of flexion
Number of subjects: 9
Study 32712103 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care lifestyle advice
Number of subjects: 122
Study 32712103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 32892184 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination Training (CT)
Number of subjects: 35
Study 32892184 — intervention group
Group type: COMPARATOR
Intervention: Resting session (control condition)
Number of subjects: 35
Study 35711602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine (DEX)
Number of subjects: 72
Study 35711602 — intervention group
Group type: COMPARATOR
Intervention: Intranasal Normal Saline (NS)
Number of subjects: 72
Study 33562180 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous use of human and dog activity trackers for eight weeks
Number of subjects: 80
Study 33562180 — intervention group
Group type: COMPARATOR
Intervention: Use of human activity trackers only
Number of subjects: 80
Study 33562180 — intervention group
Group type: COMPARATOR
Intervention: Use of dog activity trackers only
Number of subjects: 80
Study 33562180 — intervention group
Group type: COMPARATOR
Intervention: No activity trackers used
Number of subjects: 80
Study 35726861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecha kucha training via smartphone
Number of subjects: 140
Study 35726861 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge education)
Number of subjects: 140
Study 32336643 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lactate levels
Number of subjects: 55
Study 32336643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein in plasma (I‐FABPp)
Number of subjects: 55
Study 32336643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein in urine (I‐FABPu)
Number of subjects: 55
Study 32336643 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐FABPp for predicting surgical NEC
Number of subjects: 55
Study 32336643 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐FABPu for predicting surgical NEC
Number of subjects: 55
Study 35657028 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 0
Study 34463032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid (240 mg/day, supratherapeutic dose)
Number of subjects: 0
Study 34463032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34463032 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 0
Study 32042073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG) at 40% maximal handgrip force for 3 minutes
Number of subjects: 333
Study 32042073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 333
Study 32398091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables (4 servings, 300 g per day as a soup, 500-600 mL/day)
Number of subjects: 25
Study 32398091 — intervention group
Group type: COMPARATOR
Intervention: Control soup (other commonly consumed vegetables: potato, sweet potato, carrot, pumpkin)
Number of subjects: 25
Study 36271264 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 32295778 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM)
Number of subjects: 350
Study 32295778 — intervention group
Group type: COMPARATOR
Intervention: Standard in vitro fertilisation (IVF)
Number of subjects: 350
Study 32295778 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM
Number of subjects: 350
Study 32295778 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 350
Study 33568343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fractionated radiation (LDFRT) with PD-L1/CTLA-4 inhibition
Number of subjects: 18
Study 33568343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation (HFRT) with PD-L1/CTLA-4 inhibition
Number of subjects: 18
Study 33568343 — intervention group
Group type: COMPARATOR
Intervention: PD-L1/CTLA-4 inhibition
Number of subjects: 18
Study 32623230 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly income supplement
Number of subjects: 0
Study 32623230 — intervention group
Group type: COMPARATOR
Intervention: Bimonthly income supplement
Number of subjects: 0
Study 33152520 — intervention group
Group type: EXPERIMENTAL
Intervention: BTI+self‐rehabilitation (R group)
Number of subjects: 33
Study 33152520 — intervention group
Group type: COMPARATOR
Intervention: BTI alone (C group)
Number of subjects: 33
Study 32841158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexuality education program (four weekly 2-hour sessions)
Number of subjects: 102
Study 34311553 — intervention group
Group type: EXPERIMENTAL
Intervention: Authority role (neighbor, teacher, family, clergy)
Number of subjects: 0
Study 34311553 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim gender (male, female)
Number of subjects: 0
Study 34311553 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between authority role and victim gender
Number of subjects: 0
Study 34311553 — intervention group
Group type: EXPERIMENTAL
Intervention: Authority positions (teachers)
Number of subjects: 0
Study 33798214 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion storyboards
Number of subjects: 407
Study 33798214 — intervention group
Group type: COMPARATOR
Intervention: Vignettes
Number of subjects: 407
Study 32883211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided tracheal intubation (Group UG, n = 30)
Number of subjects: 60
Study 32883211 — intervention group
Group type: COMPARATOR
Intervention: Shikani optical stylet-aided tracheal intubation (Group SOS, n = 30)
Number of subjects: 60
Study 35335885 — intervention group
Group type: EXPERIMENTAL
Intervention: T-ChOS
Number of subjects: 21
Study 35335885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 32485917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromalleolar technique
Number of subjects: 110
Study 32485917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramalleolar technique
Number of subjects: 110
Study 35077638 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Energy (ME) treatment
Number of subjects: 34
Study 35077638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Velocity Low-Amplitude (HVLA) treatment
Number of subjects: 34
Study 35077638 — intervention group
Group type: COMPARATOR
Intervention: Comparison of post-first-treatment values to pre-second-treatment values
Number of subjects: 34
Study 34045002 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 containment measures
Number of subjects: 62837
Study 36062735 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity treatment (housing vouchers)
Number of subjects: 2829
Study 36062735 — intervention group
Group type: COMPARATOR
Intervention: Control group (remained in public housing)
Number of subjects: 2829
Study 33714677 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study 33714677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36283162 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway radiofrequency (RF) tissue reduction under local anesthesia (LA)
Number of subjects: 30
Study 32700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided percutaneous transhepatic biliary drainage (RPTBD)
Number of subjects: 50
Study 32700212 — intervention group
Group type: COMPARATOR
Intervention: Left-sided percutaneous transhepatic biliary drainage (LPTBD)
Number of subjects: 50
Study 32283078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad (group A)
Number of subjects: 36
Study 32283078 — intervention group
Group type: COMPARATOR
Intervention: Abdominal fat (group B)
Number of subjects: 36
Study 35979900 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic fidaxomicin (test formulation)
Number of subjects: 18
Study 35979900 — intervention group
Group type: COMPARATOR
Intervention: Original brand fidaxomicin (reference formulation)
Number of subjects: 18
Study 35979900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 33947913 — intervention group
Group type: EXPERIMENTAL
Intervention: IAsp biosimilar RD10046
Number of subjects: 30
Study 33947913 — intervention group
Group type: COMPARATOR
Intervention: NovoRapid
Number of subjects: 30
Study 32357506 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual motor competence
Number of subjects: 215
Study 32357506 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived motor competence
Number of subjects: 215
Study 36398900 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning intake of antihypertensive medications
Number of subjects: 21000
Study 36398900 — intervention group
Group type: COMPARATOR
Intervention: Evening intake of antihypertensive medications
Number of subjects: 21000
Study 33947979 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 58
Study 33947979 — intervention group
Group type: COMPARATOR
Intervention: Topical loteprednol etabonate (0.1%) and topical olopatadine (0.1%)
Number of subjects: 58
Study 33748058 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing dispensers with sunscreens (SPF 50+) at construction sites and regular feedback on application through electronic monitoring.
Number of subjects: 200
Study 33748058 — intervention group
Group type: COMPARATOR
Intervention: Basic information on UV-exposure and skin protection provided to all groups.
Number of subjects: 200
Study 33748058 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring of sunscreen consumption.
Number of subjects: 200
Study 33748058 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin check for actinic keratosis (AK) or NMSC at the end of the study.
Number of subjects: 200
Study 33748058 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of biomarkers from stratum corneum (SC) samples for internal UV-dose.
Number of subjects: 200
Study 33748058 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal UV-sensors worn by workers to assess external UV-dose.
Number of subjects: 200
Study 33748058 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sunburn episodes recorded.
Number of subjects: 200
Study 32410705 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole for 4 months
Number of subjects: 112
Study 35072215 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with pulse width of 300 µs
Number of subjects: 46
Study 35072215 — intervention group
Group type: COMPARATOR
Intervention: NMES with pulse width of 200 µs
Number of subjects: 46
Study 32503662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate (400 mg twice daily for seven days)
Number of subjects: 202
Study 32503662 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 202
Study 32503662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Number of subjects: 202
Study 37001642 — intervention group
Group type: EXPERIMENTAL
Intervention: LCA subtypes with more severe depressive symptoms
Number of subjects: 629
Study 37001642 — intervention group
Group type: COMPARATOR
Intervention: LCA mild subtype
Number of subjects: 629
Study 37001642 — intervention group
Group type: EXPERIMENTAL
Intervention: All LCA subtypes
Number of subjects: 629
Study 34886057 — intervention group
Group type: EXPERIMENTAL
Intervention: Philosophy for Children (P4C) intervention
Number of subjects: 57
Study 34886057 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 57
Study 32660475 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing intervention group (n = 99)
Number of subjects: 196
Study 32660475 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 97)
Number of subjects: 196
Study 36480230 — intervention group
Group type: EXPERIMENTAL
Intervention: New tracheal catheter fixation band
Number of subjects: 90
Study 36480230 — intervention group
Group type: COMPARATOR
Intervention: 3M strong adhesive tape
Number of subjects: 90
Study 33341066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent concretization intervention education
Number of subjects: 126
Study 33341066 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 126
Study 33781107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.44 mg/kg)
Number of subjects: 32
Study 33781107 — intervention group
Group type: COMPARATOR
Intervention: Active-placebo remifentanil
Number of subjects: 32
Study 33208099 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (30 mg/kg loading dose over 10 min, then 10 mg/kg per h until 10 min before end of surgery)
Number of subjects: 66
Study 33208099 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline, equal volume to magnesium group, same regimen)
Number of subjects: 66
Study 33208099 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 66
Study 33208099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 33345840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (fasting <90 mg/dL, 1 hour postprandial <120 mg/dL)
Number of subjects: 60
Study 33345840 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control (fasting <95 mg/dL, 1 hour postprandial <140 mg/dL)
Number of subjects: 60
Study 35710213 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates program twice a week for 10 weeks
Number of subjects: 66
Study 35710213 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily routines)
Number of subjects: 66
Study 34516759 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 254
Study 34516759 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 254
Study 34516759 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine and Active Monitoring (AM)
Number of subjects: 254
Study 33474815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral synbiotics supplement (1 sachet daily for 12 weeks)
Number of subjects: 57
Study 33474815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 sachet daily for 12 weeks)
Number of subjects: 57
Study 33474815 — intervention group
Group type: COMPARATOR
Intervention: Comparison between synbiotics and placebo at week 12
Number of subjects: 57
Study 32856566 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating Happiness© intervention
Number of subjects: 49
Study 35973827 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoHeal® 500 mg/day
Number of subjects: 40
Study 35973827 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoHeal® 1000 mg/day
Number of subjects: 40
Study 35973827 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study 33437991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST-IT)
Number of subjects: 123
Study 33437991 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 123
Study 33316649 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 27
Study 33316649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33022918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (EXP; n = 10)
Number of subjects: 20
Study 33550393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-Maze procedure
Number of subjects: 450
Study 36364870 — intervention group
Group type: EXPERIMENTAL
Intervention: CALO mama Plus (intervention group)
Number of subjects: 141
Study 36364870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 141
Study 36364870 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 141
Study 32013717 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal drain placement (G1)
Number of subjects: 84
Study 32013717 — intervention group
Group type: COMPARATOR
Intervention: No abdominal drain placement (G2)
Number of subjects: 84
Study 36203694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Brains digital intervention
Number of subjects: 360
Study 34267550 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 300 mg
Number of subjects: 106
Study 34267550 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study 33967202 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine maintenance therapy after gemcitabine + platinum combination therapy
Number of subjects: 18